Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CYBN SEC filings page on Stock Titan aggregates Cybin Inc.’s regulatory disclosures as a foreign issuer, giving investors structured access to the company’s official documents. Cybin files with the U.S. Securities and Exchange Commission primarily on Form 40-F and Form 6-K, and also uses Form 25 for listing changes. These filings are central to understanding the company’s clinical-stage neuropsychiatry business, its capital structure, and its transition between stock exchanges.
Form 6-K submissions for Cybin typically include interim consolidated financial statements, management’s discussion and analysis, certifications of interim filings, and news releases. Many 6-Ks also incorporate material change reports, equity distribution agreements, and prospectus-related documents by reference into Cybin’s registration statements on Form F-10. For a company developing drug candidates such as CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, these filings provide context on how clinical programs are funded and governed.
The filings page also features Cybin’s Form 25, which notifies the SEC of the voluntary removal of its common shares from listing and registration on the NYSE American. This document confirms that the company has complied with the exchange’s rules and the requirements for voluntary withdrawal, and it aligns with Cybin’s news release describing its plan to transfer its U.S. listing to the Nasdaq Global Market and to change its trading symbol from CYBN to HELP.
On Stock Titan, each new Cybin filing from EDGAR is captured and presented with AI-powered summaries that explain the purpose and key points of documents such as 6-Ks, F-10 registration statements, and the Form 25 delisting notice. This helps readers quickly understand how Cybin reports its financial results, documents material changes, and manages its listing status, while still allowing direct access to the underlying SEC filings for detailed review.
Cybin Inc. (CYBN) received a Schedule 13G showing that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively report beneficial ownership of 3,072,250 common shares, representing 6.09% of the class as of the reported date.
The filing lists shared voting and dispositive power over 3,072,250 shares and no sole voting or dispositive power. The ownership calculation references 50,431,381 shares, derived from 49,894,131 shares outstanding as of October 28, 2025 plus 537,250 warrants that are exercisable subject to a 9.99% Maximum Percentage beneficial ownership cap. The certification states the securities were not acquired to change or influence control.
Cybin Inc. received an amended Schedule 13G filing reporting that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively beneficially own 1,000,000 common shares, equal to 3.97% of the class. The Date of Event Which Requires Filing is 09/30/2025.
The reporting persons have shared voting and dispositive power over 1,000,000 shares and no sole voting or dispositive power. The filing indicates ownership of 5 percent or less of the class and includes a certification that the securities were not acquired to change or influence control of the issuer.
For context, the percent ownership is based on 25,188,217 common shares outstanding as of September 16, 2025, as cited from the issuer’s F-10. Information is stated as of October 29, 2025.
Cybin Inc. furnished a Form 6-K as a foreign private issuer, incorporating several exhibits by reference into its Form F-10 registration statement. The exhibits include a form of securities purchase agreement, forms of pre-funded warrant and warrant, a placement agency agreement dated October 27, 2025, and a legal consent from Aird & Berlis LLP. This connects key financing and warrant documents directly to the company’s existing Canadian short form base shelf registration on Form F-10.
Cybin Inc. (CYBN) filed a new Form D for an exempt offering under Rule 506(b). The notice covers stock options exercisable at CAD$8.39 per share, vesting in eight quarterly tranches beginning December 31, 2025.
Total amount sold is $0 USD, with $601,865 USD remaining to be sold. The company notes the total represents the maximum potential proceeds from option exercises. The filing lists a Date of First Sale: October 1, 2025, and reports $0 in finders’ fees. The issuer is incorporated in Ontario, Canada and identifies its industry as health care/biotechnology.